Saudi summit: GLP-1 drugs could revolutionize global health, access remains a challenge
A leading obesity researcher has called for broader access to revolutionary GLP-1 weight-loss drugs such as Ozempic and Wegovy at Saudi Arabia's Global HealthSpan Summit, which is highlighting the importance of longer, healthier lives.
Speaking at the second annual Global HealthSpan Summit, organized by the Kingdom's Hevolution Foundation, David Bradley Allison raised crucial questions about the future of GLP-1 drugs, which have shown remarkable effectiveness in treating obesity and potentially extending healthy lifespans.
'Who decides who gets these drugs? Who pays for them?' Allison asked, addressing the ethical considerations surrounding access to these medications. 'Should a person be able to choose to take one of these drugs for their benefits that they perceive, even if it's not judged by mainstream medicine as medically indicated?' Allison questioned, highlighting the tension between personal choice and medical oversight.
Addressing concerns about the high cost of GLP-1 drugs, Allison drew parallels with other technologies that became more affordable over time.
'People talk about how it would cripple the economy, but these are predicated on assumptions that the price doesn't come down,' he said. 'Pocket calculators were very expensive in 1970. Now you give pocket calculators away.'
The researcher also noted ongoing developments in drug delivery systems, including oral medications currently in development as alternatives to injections, which could potentially increase accessibility and reduce costs.
While acknowledging the promise of GLP-1 drugs, Allison emphasized the importance of addressing broader social and economic factors affecting public health. He cited two significant studies demonstrating the impact of environmental and educational factors on obesity rates.
The Moving to Opportunity study, a long-term randomized controlled trial by the US Department of Housing and Urban Development, showed that people who moved to better housing conditions were less likely to develop obesity and diabetes decades later.
Similarly, the Abecedarian study revealed that early intervention programs focusing on education and parent training led to lower obesity rates, particularly among women and girls.
When asked about potential policy solutions, Allison advocated for a freedom-oriented approach rather than restrictions.
'I like giving things, not taking things,' he said, suggesting that government action should focus on making anti-obesity medications more accessible while ensuring proper informed consent.
The summit was organized by the Hevolution Foundation, established by Saudi Crown Prince Mohammed bin Salman through a royal decree. The foundation commits over one billion dollars annually to research aimed at extending healthy human lifespans, representing one of the largest investments in longevity science globally.
The non-profit foundation aims to democratize access to healthspan science to benefit all of humanity, marking a significant shift in Saudi Arabia's role in global health research.
The discussion comes at a time when GLP-1 drugs have gained significant attention for their effectiveness in treating obesity and potential implications for healthy aging.
These medications work by mimicking hormones that influence appetite, fullness, and digestion, representing a potentially transformative approach to treating obesity and related conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Al Arabiya
3 days ago
- Al Arabiya
UK warns about ‘skinny jabs' if trying to get pregnant
The UK's medicine regulator warned Thursday against taking 'skinny jabs' to fight weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies. The Medicines and Healthcare Products Regulatory Agency (MHRA) said popular jabs like Ozempic and Wegovy 'must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding.' It urged women to use 'effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant.' 'Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible... because there is not enough safety data to know whether taking the medicine could cause harm to the baby,' it added. Rebecca Reynolds, a professor of metabolic medicine at the University of Edinburgh, said there was 'hardly any available data from human studies' to know if the weight loss drugs were safe in pregnancy. 'The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans,' she added. The MHRA also warned about the impact of another weight-loss and diabetes injection, Mounjaro, on the effectiveness of oral contraception for people who are overweight. 'Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception,' it said. Ying Cheong, a consultant in reproductive medicine at the University of Southampton, called the MHRA's advice 'both timely and necessary.' 'Gastrointestinal side-effects such as vomiting and diarrhea can impair oral contraceptive absorption, increasing the risk of unintended pregnancy,' he said.
Arab News
17-04-2025
- Arab News
How AI is decoding multi-omics data to boost health and longevity in Saudi Arabia
RIYADH: Saudi Arabia is embracing the future of healthcare by integrating artificial intelligence and omics-based diagnostics to deliver personalized, preventive care. This is part of a broader transformation that frames longevity not just as an individual aspiration but a national priority. Central to this transformation is the integration of genomics, proteomics, metabolomics, and other omics disciplines into clinical practice — powered by AI. Leading the charge is Rewind, a Saudi Arabia-based company using the technology to pioneer proactive, individualized care. 'At Rewind, we harness the power of AI and omics technologies to shift healthcare from a generalized, reactive model to one that is deeply personalized and proactive,' Dr. Walid Zaher, the founder of Rewind, told Arab News. 'AI is the engine that makes this vast data actionable. It identifies patterns, predicts health risks, and recommends the most effective interventions for each individual.' He said that 'such a dynamic, data-driven approach' enables healthcare to be 'as unique as the patient it serves.' • Integrating AI with omics-based diagnostics supports early disease detection and predicts health risks. • In cancer care, AI and genomics are used together to match patients with the most effective targeted therapies. • Saudi Arabia, the US, and the UK are making major investments in the integration of AI and omics. Omics refers to a group of biological fields ending with the suffix '-omics,' each examining a different layer of biological data on a system-wide scale. Together, they offer a comprehensive view of how the body functions. Transitioning from this broad understanding to actionable insights requires AI's ability to analyze trillions of variables across DNA, protein expression, metabolic changes, and epigenetic shifts. This capability allows practitioners to intervene earlier and more accurately than ever. 'Omics-based diagnostics have already begun to make a profound impact on patient outcomes,' said Zaher. 'The precision enabled by genomics and multi-omics technologies allows us to detect diseases at their earliest molecular stages — often well before any clinical symptoms appear. 'Beyond disease detection, multi-omics approaches help in monitoring disease progression and response to treatments. The result has been an increase in patient satisfaction, as they experience better health outcomes and more personalized care.' Saudi Arabia's commitment to health innovation is evident in both its infrastructure and ambition. National initiatives like the Saudi Genome Program and investments through the Hevolution Foundation are driving the development of a knowledge-based healthcare system aligned with Vision 2030. 'Saudi Arabia's Vision 2030 has made healthcare innovation a strategic priority,' said Zaher. 'The government has invested heavily in infrastructure that supports cutting-edge research, particularly in AI, genomics, and biotechnology.' This focus is positioning Saudi Arabia as a major player in the global longevity economy, according to Dmitry Kaminskiy, a co-founder and managing partner of Deep Knowledge Group. 'Saudi Arabia and its GCC counterparts are strategically positioned to be not just participants but global pioneers in the longevity economy,' Kaminskiy told Arab News. 'With Vision 2030, the Kingdom has set the foundation for integrating economic diversification, healthcare innovation, and AI governance — all key components of a national longevity strategy.' Kaminskiy, who has authored multiple books on AI and healthspan, believes that AI has shifted from a supporting role to something far more central to the field. 'We are now witnessing a paradigm shift where AI is not just an assistant but the architect of next-generation healthcare platforms,' he said. 'Just as fintech redefined personal finance, AI will redefine personal health.' Despite these advancements, significant challenges remain in mainstreaming AI and omics-based care into national systems. Zaher of Rewind noted that overcoming these hurdles will require both technological and cultural shifts. 'Integrating AI and precision medicine into a national healthcare system comes with several challenges, the most pressing of which is the need for a robust data infrastructure,' he said. 'Healthcare data is often fragmented or siloed, making it difficult to create a cohesive system that AI can utilize effectively.' Another critical challenge is training healthcare providers to engage with this new era of medicine. Zaher said the integration of AI and precision medicine into clinical practice demands 'a level of technological literacy that has yet to become widespread across the healthcare workforce. 'We need targeted training programs that equip providers with the skills to interpret AI-generated insights and translate them into actionable, patient-centered care,' he added. Looking ahead, Kaminskiy said establishing ethical data governance will be vital to ensuring progress. 'Data is the lifeblood of AI-powered longevity,' he said. 'But it is not just the amount of data that matters — it is the ownership, security, and ethical governance of that data that will define the winners in this domain.' The Hevolution Foundation is playing a key role in funding and shaping the longevity research agenda in the region. According to Zaher, it is 'poised to play a pivotal role in accelerating global healthspan science by providing the funding and resources necessary to drive innovation in aging research. 'Through supporting projects that focus on extending healthspan and preventing age-related diseases, Hevolution is helping to set a global standard for longevity science,' he added. As Saudi Arabia expands its investment in AI-driven healthcare and global collaborations deepen, the boundaries between technology, biology, and medicine are blurring — bringing the goal of healthy aging closer to reality.
Al Arabiya
27-02-2025
- Al Arabiya
AstraZeneca opens biomethane plant in UK to cut emissions
AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its research and development and drug manufacturing in Britain is powered by clean energy, it said on Thursday. The plant, operated through a 15-year agreement between AstraZeneca and UK-based biomethane producer Future Biogas, will supply 100 gigawatt hours (GW) of renewable energy per year for AstraZeneca's three R&D and manufacturing sites in the country, equivalent to 20 percent of its total gas consumption globally. Why it's important Many big companies have been dropping commitments to cutting emissions and switching to renewable energy as cost-cutting has become a major priority and US President Donald Trump's return to the White House has shifted the focus to fossil fuels. In Britain, Prime Minister Keir Starmer's government is pushing to decarbonize the country's power network with the help of private investment. AstraZeneca's new plant in Lincolnshire, eastern England, is not subsidized by the UK government. The company says its switch to renewable energy in the UK is part of a broader commitment to use 100 percent renewable energy for all of its own operations globally by the end of this year. Its commitment to a goal of net zero emissions by 2045, which it set in 2020, also depends on its suppliers using green power. Context AstraZeneca entered a similar long-term agreement in 2023 with a US company, Vanguard Renewables, that enabled it to transition to biogas from natural gas and cut its emissions across its US research and manufacturing sites. The company aims to reduce greenhouse gas emissions it directly produces by 98 percent by 2026, from a 2015 baseline. Though Danish drugmaker Novo Nordisk has set similar targets to reduce its carbon footprint, it said earlier this month that its emissions grew 23 percent in 2024 and will keep rising through the end of the decade as it boosts production of its blockbuster obesity drug Wegovy.
